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Oral Presentations S191antagonist approved for the prevention of acute and delayed CINV
associated with initial and repeat courses of moderately and highly
emetogenic chemotherapy in combination with other antiemetics.
We evaluated the outcomes of ondansetron and dexamethasone
compared with aprepitant, ondansetron, and dexamethasone in pa-
tients undergoing autologous HSCT, with BEAM or Melphalan
conditioning, in a randomized single center clinical trial. Patients
were randomized to receive either ondansetron and dexamethasone
on the days of chemotherapy followed by 3 days of dexamethasone
(OD) or OD combined with aprepitant 125 mg on the first day of
conditioning, followed by aprepitant 80 mg daily until day
0 (AOD). Rescue antiemetics were allowed. Acute phase was
defined as each day (24-hr period) of chemotherapy. Delayed phase
was defined as the 5 days (0 – 120 hrs) following the last dose of
chemotherapy. Complete response (CR) was defined as no emesis
or rescue antiemetics in a 24-hour period. Major response (MaR)
was defined as 1 episode of emesis or the need for rescue anti-
emetics in a 24-hour period. Twenty-four patients were random-
ized to each arm. Age, gender, prior history of CINV, and
conditioning regimen were similar between OD and AOD. There
were no significant differences between the two arms in the rates
of acute or delayed nausea, CR, and MaR (Table 1). Despite pre-
medication, almost all of the patients experienced nausea and/or
vomiting after the completion of the study period up to day +30
(OD 100% and AOD 83.3%; p5 0.11). Grade 3/4 nonhematologic
toxicity was similar between the two groups. The most common
toxicities reported were nausea, hypophosphatemia, anorexia, and
infection. Although the CR rates for acute and delayed emesis
were greater in AOD, the addition of aprepitant did not signifi-
cantly improve CINV control in this small autologous HSCT
population.Table 1. Antiemetic Response Rates
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Background:The optimal dosing of MMF in pediatric AlloSCT re-
cipients is unknown.
Objective: To determine MMF PK in pediatric AlloSCT recipi-
ents\12 years of age.
Methods:GVHDprophylaxis included tacrolimusDay –1 (5-20 ng/
mL) and MMF 900 mg/m2 IV Q6H starting on Day +1, then con-
verted to PO (same dose) after Day +14. MPA serum samples were
drawn on Days +1, +7, +14 (IV phase) and twice between Day +45-
+100 (PO phase) at hour 0, 0.5, 1, 2, 3, 4, 6 post-dose. MPA plasma
concentrations were determined by reverse-phase HPLC and LC/
MS/MS. Non-compartmental PK analysis of total MPA was
performed.
Results: PK was completed in 25 pts: mean age 5 yrs; M:F 12:13;
14 pts\6 yrs & 11 pts 6-12 yrs; 11 pts non-malignant & 14 with
malignant disease; 14 pts received unrelated AlloSCT. Patients
with non-malignant disease received reduced-intensity condition-
ing. Median time to myeloid and platelet engraftment was 21
and 33 days, respectively. KM probability of Grade II-IV acute
GVHD (aGVHD) and limited + extensive chronic GVHD was
52% and 39.8%, respectively. Probability of 1 year OS was
78.8% (CI95: 62%-95%). There was a significant inter- and intra-
patient variability in AUC0-6 and MPA trough (C0) (Table 1).
There was no significant difference in MMF PK between
pts\6 vs 6-12 yrs of age following IV or PO MMF administra-
tion. Univariate analyses did not find a correlation between
AUC, C0 or Css on Days 7 or 14 and risk of aGVHD. There
was a significant [ in MPA trough on day 7 vs 1 (P5 0.009),
[AUC on day 14 vs 7 (P5 0.049) and Y Vss day 14 vs day 1 &
7 (P5 0.001). There was also a significant [ T1/2 on day 45 vs
day 1 and 7 (P5 0.043 and P5 0.042, respectively) as well as [
CLss and Vss on day 45 vs day 14 (P5 0.01 for CLss and
P5 0.006 for Vss).
Conclusion: This change in PK parameters with time could be due
to improved mucosal healing following conditioning that leads to
improved drug absorption and enterohepatic recirculation. Based
on these results, we recommend reducing MMF dose to 600-
900 mg/m2 q8 h in the early post-transplant period in children
\12 yrs of age to target Css5 2.5-5 mg/L (Nash et al, BBMT
2005).96
EVALUATION OF THE INITIAL DOSE CALCULATION OF INTRAVENOUS BU-
SULFAN (BUSULFEX) IN ADULTS RECEIVING A CONVENTIONAL BU/
CY2 ALLOGENEIC PREPARATIVE REGIMEN
O’Neal, N.K., DuBois, L.K., Williams, C.B., Casey, K.L., Aljitawi, O.S.,
Ganguly, S., Abhyankar, S., McGuirk, J.P. The University of Kansas
Hospital, Kansas City, KS
Several studies have reported that the variability in pharmacoki-
netic (PK) parameters after intravenous busulfan dosing is signifi-
cantly lower than that recorded after dosing with the oral
formulation. However, other published experiences have concluded
that both the oral and intravenous formulation of busulfan yield wide
interpatient variability in PK parameters.MMF PO 1st sample MMF PO 2nd sample
y 114 (N5 23) Day 145-100 (N5 13) Day 145-100 (N5 7)
17.86 15.2 13.46 12.8 13.56 8.4
1.876 0.34 1.656 1.05 1.366 0.85
0.686 0.64 1.396 1.44 1.666 1.48
6.356 3.11 5.006 3.46 7.226 3.70
36.66 18.6 26.46 20.6 27.456 16.0
1.306 0.63 2.326 1.42 1.616 1.02
3.006 1.02 10.436 8.99 21.226 38.25
1.256 1.02 2.986 2.38 12.786 20.58
S192 Oral PresentationsMultiple investigators have determined that the average bio-
availability of oral busulfan is estimated to be 70-80%. Based
upon the established 1 mg/kg/dose of oral busulfan, the intravenous
equivalent was established at 0.8 mg/kg/dose given every 6 hours.
The primary purpose of this evaluation is to determine if 0.8 mg/
kg is the most appropriate starting dose for all populations and
will reliably provide a therapeutic area under the curve (AUC) for
a majority of the patients. Additionally, this evaluation will review
the effect of using adjusted versus actual body weight for the initial
dosing of busulfan.
A retrospective review was completed in 28 patients that re-
ceived targeted busulfan given every 6 hours as a component of
the Bu/Cy2 preparative regimen for allogeneic transplant from
9/07 to 9/09. Initial busulfan dosing was started at 0.8 mg/kg on
actual body weight unless the patient was. 30% over ideal body
weight and then an adjusted body weight calculation was utilized.
Since our dose adjustments are based on a target AUC of
1100 mMol/min, 61% (17/28) required dose increases. AUC levels
of# 900 mMol/min were observed in 6 out of 28 patients (28%). In
addition, 5 out of the 6 patients that had an AUC# 900 mMol/min
were initially dosed based upon an adjusted body weight. Of all pa-
tients requiring dose increases, 10/17 (59%) were significantly
overweight with a range of 31-112% over ideal body weight.
Only 1 patient (4%) fell into the supratherapeutic range with an
AUC. 1500 mMol/min and this patient was heavily pretreated
and had underlying hepatic dysfunction. See table 1 for summary
of data.
Based upon our data, it appears that we are initially underdosing
busulfan in a number of patients. Further analysis is required before
significant changes are made to our current approach, but our data
suggests that we need to increase our starting dose to at least
0.9 mg/kg/dose in a majority of our patients.
Table 1. Data Summary
Initial TargetedGender
Age
(yr)AUC
(mMol/min)Clearance
(mL/min)/kgActual
weight
(kg)Dosing
weight
(kg)Busulfan
Dose
(mg)Busulfan
Dose
(mg)F 59 823 4 72.7 58.5 47 62
F 37 832 3.9 74.8 59 47 62
M 59 843 3.7 83.6 83 66 86.2
M 47 857 3.8 73.4 62.8 50 64.2
M 50 882 3.7 102 84 56 70
F 42 900 3.6 131 89.3 72 88
M 60 920 3.5 108 88.3 70 83.7
F 48 924 3.5 108 75 60 71.4
M 46 927 3.5 82.7 82.7 66 78
M 57 946 3.4 96.8 96.8 77 89.6
M 49 956 2.9 106 90.3 72 83
M 56 957 3.4 84 84 67 77
M 30 961 3.4 82.3 82.3 66 77.5
M 56 970 2.6 102 84.6 68 77
M 51 1031 3.2 82 82 66 70
F 60 1047 3.1 85 69.5 56 59
M 46 1060 3.1 82.5 82.5 66 68.5
F 45 1081 3 79 65.8 52 52.9
F 49 1117 2.9 62 62 50 49.2
M 51 1152 2.7 100 100 80 76.4
M 47 1193 3.4 85 85 68 62.7
M 52 1196 2.7 100 100 80 74
F 49 1222 2.7 88 68.6 55 50
M 61 1310 2.5 93.8 93.8 75 63
F 53 1367 2.4 56 56 45 36.2
M 56 1423 2.6 91 91 73 56
M 25 1426 2.3 76 76 61 47
F 35 2214 1.5 100 71.5 57 28If dosing weight differs from actual weight, then adjusted body weight
calculation was utilized as follows: adjusted weight5 ideal weight1 0.4
(actual weight – ideal weight).97
A COMPARISON OF TOXICITY AND MOBILIZATION EFFICACY FOLLOW-
ING TWO DIFFERENT DOSES OF CYCLOPHOSPHAMIDE FOR MOBILIZA-
TION OF HEMATOPOIETIC STEM CELLS IN MULTIPLE MYELOMA
PATIENTS
Sizemore, C.A., LaPorte, J., Sanacore, M.F., Holland, H.K.,
Mccollum, J., Westerman, J., Morris, L.E., Bashey, A., Solomon, S.R.
Blood and Marrow Transplant Program at Northside Hospital, Atlanta,
GA
Background:Cyclophosphamide (Cy) (2-7 g/m2) has been shown
to be an effective regimen for hematopoietic stem cell (HSC)
mobilization in multiple myeloma (MM) patients undergoing au-
tologous stem cell transplantation (ASCT). The optimal dose to
be used, which maximizes HSC collection yields while minimiz-
ing febrile neutropenia and other toxicities, remains controver-
sial. Two cohorts of MM patients who received G-CSF and
Cy at dose of either 4 g/m2 (Cy4) or 2 g/m2 (Cy2) were com-
pared.
Methods: 72 patients undergoing first mobilization with Cy and G-
CSFatasingleinstitutionbetween6/06and12/08wereretrospectively
analyzed.TheinitialCy4patientcohort(n5 35)wasmobilizedwithCy
4gm/m2 starting onDay 1 followed byG-CSF(10ug/kg/day) starting
on Day 7 and continuing until completion of apheresis. In 2/08, the
Cy dose was reduced to 2gm/m2 and theG-CSF start date wasmoved
today4(Cy2 n5 37).Minimalandoptimalyieldwasdefinedascollec-
tionof$2106and$6-10106CD34+cells/kgrespectively.Prophy-
lactic antibiotics were given for ANC\500 to reduce risk of febrile
neutropenia.
Results: Minimal cell dose required for ASCT was achieved in
97% vs. 86.5% of Cy4 and Cy2 patients, respectively. Of the 5 pa-
tients failing to mobilize on Cy2, four of these subsequently mo-
bilized adequately following G-CSF and plerixafor. Median
number of apheresis collections required was significantly lower
in the Cy4 patients (1 vs.3, p5 0.0065). The proportion of pa-
tients collecting the minimal and optimal cell dose in 2 or fewer
days of apheresis was 94% vs. 86.5% (p5 0.4304) and 77% vs.
35% (p5 0.0004), in the Cy4 and Cy2 patients respectively. Mo-
bilization with Cy4 was associated with a significantly higher inci-
dence of hospital admissions due to febrile neutropenia (40% vs.
5%, p5 0.0005).
Conclusions: Although Cy4 and Cy2 are both effective HSC
mobilizing regimens, mobilization efficacy and toxicity vary
greatly. Cy4 results in higher HSC yields requiring fewer apheresis
procedures, but this benefit is offset by increased morbidity and
hospitalization. Based on the suboptimal results with Cy 4 g/m2
and Cy 2 g/m2 mobilization, we are currently exploring a chemo-
therapy-free approach utilizing G-CSF +/- plerixafor, with the
aim of optimizing HSC yields while minimizing toxicity and costs.
Patients receive G-CSF(10ug/kg/day), with a day 4 peripheral
CD34+ cell count determining requirement for plerixafor prior
to apheresis.Cy 4gm/m21 Cy 2gm/m21
G-CSF n5 35 G-CSF n5 37 P Value% of Patients who
achieved$ 2 x 106 CD341
cells/kg in# 2 days94% (33/35) 86.5% (32/37) P5 0.4304% of Patients who
achieved$ 6 x 106
CD341cells/kg in# 2 days77% (27/35) 35% (13/37) P5 0.0004% of Patients who
failed to collect$ 2 x 106
CD341 cells/kg2.8%(1/35) 13.5% (5/37) P5 0.1998% of Patients who failed
to achieve$ 6 x106
CD341cells/kg17% (6/35) 37.8% (14/37) P5 0.0668Median (range) days
of collection in all patients1 (1-6) 3 (1-6) P5 0.0065% Patients hospitalized
for febrile neutropenia40% (14/35) 5% (2/37) P5 0.0005
